Advertisement

Topics

PureTech’s Milk Exosome-Based Technology Draws R&D Pact With Roche

08:24 EDT 20 Jul 2018 | SCRIP

PureTech's milk-derived exosome platform will be used by Roche to generate numerous novel antisense oligonucleotides, potentially earning PureTech more than...

      

Related Stories

 

Original Article: PureTech’s Milk Exosome-Based Technology Draws R&D Pact With Roche

NEXT ARTICLE

More From BioPortfolio on "PureTech’s Milk Exosome-Based Technology Draws R&D Pact With Roche"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...